COVID19 Vaccination: Clinical, Laboratory & Cellular Monitoring

Status Recruiting

Clinical Trial Summary

Primary objective: 1. Monitor adverse events (Adverse Event Following Immunization - AEFI) in vaccinated subjects and analyze the associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities. Secondary objectives: 1. Monitor the antibody response in vaccinated subjects and analyze the associations with: (a) demographic variables and anthropometric parameters (sex, age, BMI, etc.); (b) socioeconomic-cultural variables; (c) co-morbidities. 2. Assess the quantity (antibody titer) and quality of the anti-Spike immune response induced by vaccination. 3. Evaluate the dynamics of the infection and the protective efficacy of the vaccine against infection / disease by studying the incidence and titre of antibodies against Nucleoprotein (N) induced by natural infection; 4. Evaluate the neutralizing capacity of sera vs. a panel of sera selected and analyzed in house and in in vitro microneutralization systems with live virus; 5. To evaluate the cell-mediated immune response (CMI) to vaccination against SARS-CoV-2 in a subgroup of vaccinees. Methodology: 1. Administration at baseline of a questionnaire for the collection of clinical data. 2. Perform a blood sample to measure antibody response in vaccinated subjects 3. Administer a questionnaire to evaluate adverse events after vaccination 4. Reassess the antibody response 1 month after complete vaccination and 6 and 12 months after the start of vaccination 5. An antibody assay will be drawn in a subgroup before subjecting the subject to the vaccine. 6. In a subgroup, the blood collected will also be collected in a heparinized tube for the study of cell-mediated immunity. 7. In the event that a subject participating in the study presents during the course of the observation the positivity for the molecular research of SARS-CoV-2 RNA to the oro-nasopharyngeal swab, a new sample will be performed and sent to the Istituto Superiore di Sanità for the search for viral variants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04844632
Study type	Observational
Source	University of Roma La Sapienza
Contact	Stefania Basili, MD
Phone	+393393452523
Email	stefania.basili@uniroma1.it
Status	Recruiting
Phase
Start date	February 11, 2021
Completion date	May 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05596474` - Effect of Beet-root Juice and PBM Treatments on Muscle Fatigue	N/A
Recruiting	`NCT05778578` - Universal Basic Income and Structural Racism in the US South	N/A
Not yet recruiting	`NCT05558332` - Youth Nominated Support Team	N/A
Completed	`NCT02451059` - Reducing Socioeconomic Disparities in Health at Pediatric Visits	N/A
Completed	`NCT05082935` - COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos) Phase II	N/A
Recruiting	`NCT05454969` - One-4-ALL Initiative	N/A
Enrolling by invitation	`NCT05045222` - Economic and Clinical Outcomes of (Whole Exome) Sequencing in Tapestry
Completed	`NCT04587063` - Evaluation of Emails Promoting Mail-order Pharmacy	N/A
Recruiting	`NCT05541913` - The Effect of Tele-Nursing on Parents of Circumcised Children	N/A
Completed	`NCT05117333` - Reminders, Cost Sharing, and Healthcare Use	N/A
Recruiting	`NCT04835012` - Health and Health Care Utilization Effects of Medical Debt Forgiveness
Completed	`NCT04567342` - Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of MMR Vaccination	N/A
Withdrawn	`NCT05552638` - Telecare in Rural Senior Centers	N/A
Enrolling by invitation	`NCT04250103` - Home-based Longitudinal Investigation of the Multidisciplinary Team Integrated Care
Completed	`NCT04240093` - CoMBAT Opioid Use Disorder: A Combined Medication and Behavioral Activation Treatment for People Living With Opioid Use Disorder	N/A
Active, not recruiting	`NCT03724695` - Advanced Heart Care at Home	N/A
Completed	`NCT04517578` - European Neuromuscular Monitoring Survey
Active, not recruiting	`NCT05609188` - Black Economic Equity Movement	N/A
Completed	`NCT04373135` - Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19	N/A
Recruiting	`NCT05324566` - Evaluation of ECG Transmission and AI Models Using Apple Watch ECGs and Symptoms Data Collected Using a Mayo iPhone App

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring — SAPIENZAVAX

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms